Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anteris Technologies Global Corp. ( (AVR) ) has shared an announcement.
On March 21, 2025, Anteris Technologies Global Corp. announced favorable one-year patient outcomes for its DurAVR® Transcatheter Heart Valve (THV) System. The results, presented at Sydney Valves, highlighted the valve’s sustained hemodynamic performance and zero prosthesis-patient mismatch (PPM) in small annuli patients, a significant achievement compared to current commercial devices. These outcomes reinforce the potential of DurAVR® as a transformative solution in the transcatheter aortic valve replacement (TAVR) market, with implications for improved long-term patient outcomes and plans for a global pivotal study.
More about Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function. The company, founded in Australia with a significant presence in Minneapolis, USA, is known for its lead product, the DurAVR® Transcatheter Heart Valve (THV), which is designed to treat aortic stenosis using its patented anti-calcification tissue technology.
YTD Price Performance: 11.89%
Average Trading Volume: 129,408
Find detailed analytics on AVR stock on TipRanks’ Stock Analysis page.